Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05729932 · ClinicalTrials.gov registry record · Phase 1
Cannabis and Opioid Use Disorder
A Phase 1 study of Opioid Use Disorder, sponsored by University of Kentucky.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05729932: Recruiting Phase 1 study of Opioid Use Disorder, sponsored by University of Kentucky.
NCT05729932 is a Phase 1 study of Opioid Use Disorder that is actively recruiting participants, run by University of Kentucky. The registered enrollment target is 15 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05729932, a Phase 1 study of Opioid Use Disorder, is actively recruiting participants, sponsored by University of Kentucky.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.
Primary Outcome
Subjective ratings of opioid withdrawal severity on visual analog scale (scale 0-100; 0 = not at all, 100 = extremely)
Conditions Studied
Interventions
- DRUG Inhaled vaporized cannabis
- DRUG Intransal opioid
Study Locations (1)
Kentucky
- Center on Drug and Alcohol Research - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT05729932 shows while recruiting
NCT05729932 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Inhaled vaporized cannabis is the first listed.
NCT05729932 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05729932 about?
NCT05729932 is a clinical study titled "Cannabis and Opioid Use Disorder". This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.
What is the current status of trial NCT05729932?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-10. Estimated completion is 2027-06-30.
What conditions does trial NCT05729932 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT05729932?
The interventions under investigation include: Inhaled vaporized cannabis (DRUG), Intransal opioid (DRUG).
Who is sponsoring clinical trial NCT05729932?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05729932 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05729932's enrollment target sits among peer trials
15 242nd of 257 higher than 11 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
RECRUITING · Phase 1
-
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
RECRUITING · Phase 1
-
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
RECRUITING · Phase 1
-
A Bundled Intervention
RECRUITING · Phase 1
-
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
RECRUITING · Phase 1
-
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI